Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
This is a phase II study of the drug, pegylated interferon alfa-2b (PEG-Intron), used to
treat brain tumors in a pediatric population. Researchers want to see if treatment with
PEG-Intron will stop tumor growth for patients with juvenile pilocytic astrocytomas or optic
pathway gliomas.
The purposes of this study are:
- To learn more about the response to pegylated interferon
- To learn more about the side effects of pegylated interferon
- To learn more about MRI images in patients with Juvenile Pilocytic Astrocytomas or Optic
Pathway Gliomas.
- To learn more about quality of life in patients treated with pegylated interferon